Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies

Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical successes in management of malignant tumors. As the first monoclonal antibody targeting immune checkpoint molecules entered into clinics, the molecular basis of ipilimumab-based anti-CTLA-4 blockade has not yet bee...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: He, Mengnan, Chai, Yan, Qi, Jianxun, Zhang, Catherine W.H., Tong, Zhou, Shi, Yi, Yan, Jinghua, Tan, Shuguang, Gao, George F.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620161/
https://ncbi.nlm.nih.gov/pubmed/28978021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars